The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Cancer treatment and survivorship statistics, 2022
Open accessAbstract
The number of cancer survivors continues to increase in the United States due to the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate triennially to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries, vital statistics from the Centers for Disease Control and Prevention’s National Center for Health Statistics, and population projections from the US Census Bureau. Current treatment patterns based on information in the National Cancer Database are presented for the most prevalent cancer types by race, and cancer‐related and treatment‐related side‐effects are also briefly described. More than 18 million Americans (8.3 million males and 9.7 million females) with a history of cancer were alive on January 1, 2022. The 3 most prevalent cancers are prostate (3,523,230), melanoma of the skin (760,640), and colon and rectum (726,450) among males and breast (4,055,770), uterine corpus (891,560), and thyroid (823,800) among females. More than one‐half (53%) of survivors were diagnosed within the past 10 years, and two‐thirds (67%) were aged 65 years or older. One of the largest racial disparities in treatment is for rectal cancer, for which 41% of Black patients with stage I disease receive proctectomy or proctocolectomy compared to 66% of White patients. Surgical receipt is also substantially lower among Black patients with non‐small cell lung cancer, 49% for stages I‐II and 16% for stage III versus 55% and 22% for White patients, respectively. These treatment disparities are exacerbated by the fact that Black patients continue to be less likely to be diagnosed with stage I disease than White patients for most cancers, with some of the largest disparities for female breast (53% vs 68%) and endometrial (59% vs 73%). Although there are a growing number of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence‐based strategies and equitable access to available resources are needed to mitigate disparities for communities of color and optimize care for people with a history of cancer. CA Cancer J Clin. 2022;72:409‐436.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Self-citationHaugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Self-citationVirtually perfect? Telemedicine for COVID-19
Hollander, J. E., & Carr, B. G. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2003539 · Cited by 2,970
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
How Structural Racism Works — Racist Policies as a Root Cause of U.S. Racial Health Inequities
Bailey, Z. D., Feldman, J. M., & Bassett, M. T. (2021) · New England Journal of Medicine · doi:10.1056/nejmms2025396 · Cited by 1,598
Duration of adjuvant chemotherapy for stage III colon cancer
Grothey, A., Sobrero, A. F., Shields, A. F., Yoshino, T., Paul, J., Taieb, J., Souglakos, J., Shi, Q., Kerr, R., Labianca, R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713709 · Cited by 1,092
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3809 · Cited by 1,071
Howard-Anderson, J., Ganz, P. A., Bower, J. E., & Stanton, A. L. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr541 · Cited by 830
Care for the cancer caregiver: A systematic review
Applebaum, A. J., & Breitbart, W. (2013) · Palliative and Supportive Care · doi:10.1017/s1478951512000594 · Cited by 352
Wang, L., Guyatt, G. H., Kennedy, S. A., Romerosa, B., Kwon, H. Y., Kaushal, A., Chang, Y., Craigie, S., de Almeida, C. P. B., Couban, R. J., et al. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.151276 · Cited by 334
Symptom Burden and Quality of Life in Survivorship: A Review of the Literature
Wu, H.-S., & Harden, J. K. (2015) · Cancer Nursing · doi:10.1097/ncc.0000000000000135 · Cited by 329
A systematic review of the impact of stigma and nihilism on lung cancer outcomes
Chambers, S. K., Dunn, J., Occhipinti, S., Hughes, S., Baade, P., Sinclair, S., Aitken, J., Youl, P., & O’Connell, D. L. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-184 · Cited by 258
Poghosyan, H., Sheldon, L. K., Leveille, S. G., & Cooley, M. E. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.03.013 · Cited by 198
Clement, S. C., Peeters, R. P., Ronckers, C. M., Links, T. P., van den Heuvel-Eibrink, M. M., Nieveen van Dijkum, E. J. M., van Rijn, R. R., van der Pal, H. J. H., Neggers, S. J., Kremer, L. C. M., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.09.001 · Cited by 197
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., Zakai, N., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20061 · Cited by 188
Prevalence of pain in patients with breast cancer post-treatment: A systematic review
Wang, K., Yee, C., Tam, S., Drost, L., Chan, S., Zaki, P., Rico, V., Ariello, K., Dasios, M., Lam, H., et al. (2018) · The Breast · doi:10.1016/j.breast.2018.08.105 · Cited by 176
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Rivera, E., & Cianfrocca, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2607-5 · Cited by 159
A systematic review of psychosocial interventions to improve cancer caregiver quality of life
Waldron, E. A., Janke, E. A., Bechtel, C. F., Ramirez, M., & Cohen, A. (2013) · Psycho-Oncology · doi:10.1002/pon.3118 · Cited by 147
Islam, J. Y., Vidot, D. C., & Camacho-Rivera, M. (2021) · JCO Oncology Practice · doi:10.1200/op.20.00752 · Cited by 62
Cited by
Breast Cancer Statistics, 2022
Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A., Jemal, A., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21754 · Cited by 2,286
Self-citationQi, J., Li, M., Wang, L., Hu, Y., Liu, W., Long, Z., Zhou, Z., Yin, P., & Zhou, M. (2023) · The Lancet Public Health · doi:10.1016/s2468-2667(23)00211-6 · Cited by 530
Kratzer, T. B., Bandi, P., Freedman, N. D., Smith, R. A., Travis, W. D., Jemal, A., & Siegel, R. L. (2024) · Cancer · doi:10.1002/cncr.35128 · Cited by 512
Self-citationFinancial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes
Smith, G. L., Lopez-Olivo, M. A., Advani, P. G., Ning, M. S., Geng, Y., Giordano, S. H., & Volk, R. J. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7305 · Cited by 437
Circular RNA: a novel biomarker and therapeutic target for human cancers
Lei, B., Tian, Z., Fan, W., & Ni, B. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.28047 · Cited by 313
Metadata
- Authors
- Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2022-06-23
- Volume
- 72
- Issue
- 5
- Pages
- 409-436
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W4283313052
- Cited by
- 3,597
- References
- 33
- FWCI
- 244.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.